NYSE:ALC

Track all markets on TradingView - Prices are not updated in real time
Alcon Falls 6.8% After Hours as Narrowed Outlook Overshadows Q3 Growth

Alcon (NYSE: ALC) shares fell about 6.8% in after-hours trading after the eye-care company reported third-quarter growth but narrowed parts of its 2026 outlook and highlighted continued competitive pressure in its implantables business.

Third-quarter sales rose 5% year over year to $2.72 billion, while diluted EPS increased 13% to $0.54. Core diluted EPS rose 15% to $0.91, and core operating margin improved to 21.8% from 20.2% a year earlier.

Growth was broad but uneven. Surgical sales increased 4%, with consumables up 6% and equipment and other revenue up 11%. However, implantables sales declined 2% to $422 million as U.S. competitive pressure weighed on intraocular lens sales, partially offset by strong PanOptix Pro demand and international growth. Vision Care revenue increased 6%, led by an 8% rise in ocular health sales.

Operating income increased 15% to $381 million, helped by manufacturing efficiencies and $58 million of tariff refunds. Core operating income rose 13% to $591 million.

The key investor concern appears to be the updated outlook. Alcon now expects constant-currency sales growth of about 6%, versus its previous 5%-7% range. Core operating margin expansion was narrowed to 100-150 basis points from 90-190 basis points, while core EPS growth was tightened to 12%-14% from 12%-15%.

Management also said competitive pressures remain in some areas and expects roughly $40 million of net tariff impact for the full year, with about two-thirds of a recent tariff refund being reinvested into the business.

The 6.8% after-hours decline therefore appears to reflect disappointment with the tighter earnings outlook and ongoing U.S. implantables pressure, despite solid Q3 sales growth, margin expansion and double-digit core EPS growth.
💬
Author
Global Finance News 11-11-26
Alcon Stock Rises 3.5% After Hours as Q2 Sales Grow and 2026 Profit Outlook Improves

Alcon (NYSE: ALC) shares rose about 3.5% in after-hours trading after the eye-care company reported solid second-quarter 2026 growth and raised its full-year profitability and earnings outlook.

Second-quarter sales reached $2.78 billion, up 8% year-over-year on a reported basis and 7% in constant currency. Core diluted EPS increased 11% to $0.84 from $0.76 a year earlier.

New Products Drive Growth

Alcon attributed the quarter's momentum partly to newer products including UNITY, PanOptix Pro and TRYPTYR.

The Surgical segment generated approximately $1.57 billion in sales, up 8%, while Vision Care sales increased 8% to about $1.21 billion. Equipment and other surgical sales were particularly strong, jumping 26%, driven by recent launches including the UNITY platform. Ocular health sales increased 13%, supported by dry-eye products including TRYPTYR and Systane.

Underlying profitability also strengthened. Core operating income rose 17% to $574 million, while core operating margin expanded to 20.6% from 19.1% a year earlier.

Reported results were considerably weaker because Alcon recorded a $402 million pre-tax non-cash charge related to discontinuing the PowerVision IOL programs. That charge pushed reported diluted EPS to $0.00, compared with $0.35 last year, but does not affect the company's cash position or long-range financial objectives.

Alcon Raises 2026 Earnings Outlook

The guidance update appears to be an important factor behind the positive after-hours reaction.

Alcon maintained its constant-currency sales growth forecast at 5%-7%, but raised expected core operating-margin expansion to 90-190 basis points from 70-170 basis points. The company also increased its 2026 core diluted EPS growth forecast to 12%-15%, compared with its previous 10%-13% range.

Alcon also returned $469 million to shareholders during Q2 through dividends and share repurchases, bringing year-to-date capital returns to $538 million.

The roughly 3.5% after-hours gain suggests investors are focusing on the combination of healthy organic growth, improving core margins, successful new-product launches and a stronger earnings outlook, while largely looking through the sizable but non-cash PowerVision charge.
💬
Author
Global Finance News 08-11-26